Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance

AbbVie IncTrade
State Street Technology Select Sector SPDR ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? AbbVie Inc trades at $248.69 (market cap $441.94B), while State Street Technology Select Sector SPDR ETF trades at $188.39. The key difference: AbbVie Inc pays a 2.77% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals.

ABBVXLK
Market Cap
$441.94B
Sector
HealthSector/Thematic
52-Week High
$263.58$198.21
52-Week Low
$197.38$127.49
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.

Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.

State Street Technology Select Sector SPDR ETF

XLK trades at $189.38, up 1.64% with strong technical momentum as moving averages signal bullish conditions. The Technology Select Sector SPDR Fund shows institutional interest with record sector ETF inflows of $25 billion in July 2026 (ETF Trends, 2026-08-10). Recent earnings strength from holdings like Microsoft supports the fund's performance, though RSI levels suggest potential near-term overbought conditions.

Outlook remains positive given sector earnings growth and AI-driven momentum, but risks include concentration in mega-cap stocks and valuation concerns. The fund's heavy reliance on top holdings creates sensitivity to individual company performance, requiring careful monitoring of diversification benefits.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About State Street Technology Select Sector SPDR ETF

XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.

Read more on XLK